Q1 FY 20 Performance Update

We continued on our improvement journey in Q1 FY 20 Revenues EBIDTA* Free Cash Flow INR 3,844 Cr INR 1,134 Cr INR 850 Cr (YoY growth: 3%) PBT * INR 850 Cr (YoY growth: 70%) (% of Sales: 29.5%) R&D Expenses INR 361 Cr (% of Sales: 9.4%) Net Debt/Equity 0.04 * Includes Rs. 346 cr received from Celgene towards settlement of any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company's ANDS for a generic version of REVLIMID brand capsules, (Lenalidomide) pending before Health Canada PROPRIETARY

View entire presentation